FLT3 and acute myeloid leukemia: The other occurs in cells which, albeit having a highly active RAS/MEK/ERK, bypass MEK inhibition using the FLT3/STAT5 axis; a pathway known to sustain AML viability and proliferation by acting in parallel to RAS/MEK/ERK signaling [10, 11].